Envestnet Asset Management
ACRS icon

Envestnet Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Envestnet Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-948
Closed -$24K – 2956
2017
Q3 		$24K Buy
948
+63
+7% +$1.69K ﹤0.01% 2456
2017
Q2 		$24K Buy
+885
New +$24.1K ﹤0.01% 2557

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Envestnet Asset Management's ACRS Position: Q4 2017 in Review

Envestnet Asset Management sold out of Aclaris Therapeutics (ACRS) in Q4 2017, closing a stake of 948 shares — an estimated $24K sold.

Envestnet Asset Management first reported a position in ACRS in Q2 2017 and held it in 2 quarters. The position peaked at $24K in Q3 2017. 102 funds tracked by Wall St. Rank hold ACRS as of Q4 2017.

  • Envestnet Asset Management reported no remaining Aclaris Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Envestnet Asset Management sold 948 Aclaris Therapeutics shares in Q4 2017, an estimated $24K.
  • Envestnet Asset Management first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 2 quarters.
  • Envestnet Asset Management's Aclaris Therapeutics position peaked at $24K in Q3 2017.
  • 102 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2017.

Based on Envestnet Asset Management's 13F filing for Q4 2017, filed 20 Feb 2018.